ALX Oncology Holdings Inc., a clinical-stage biotechnology company, announced that it has received clearance for its Investigational New Drug $(IND.AU)$ application from the U.S. Food and Drug Administration for its novel antibody-drug conjugate, ALX2004. This clearance marks a significant step forward in the clinical development of ALX2004, which targets EGFR-expressing tumors and is designed to optimize anti-tumor activity. The IND approval allows ALX Oncology to begin clinical trials to further evaluate the safety and efficacy of ALX2004, which has been fully designed and developed by the company's scientists. The announcement underscores ALX Oncology's commitment to advancing innovative therapies to treat cancer and improve patient outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.